Healthcare Distribution Alliance – Patients Move Us.
Share Print
News

News

FEATURED NEWS

Results: 28 Articles found.
  • HDA Statement on Senate Passage of Legislation to Address Opioid Abuse Epidemic
    September 17, 2018

    Healthcare Distribution Alliance (HDA) President and CEO John M. Gray released the following statement on the Senate passage of comprehensive opioid legislation, the SUPPORT for Patients and Communities Act (H.R. 6).

  • HDA Research Foundation Report Analyzes Reverse Distribution of Pharmaceutical Products
    August 6, 2018

    A new report published by the HDA Research Foundation entitled The Role of Reverse Distribution provides insights into the reverse distribution of pharmaceutical products. The Foundation estimates that this channel accounts for 3.5 to 4 percent of all pharmaceutical sales — more than 120 million product units — and exceeds $13 billion in product value.

  • HDA Statement on FDA Work Group to Examine Prescription Drug Importation
    July 20, 2018

    Healthcare Distribution Alliance (HDA) President and CEO John M. Gray released the following statement on the Department of Health and Human Services’ (HHS) recent directive to establish a Food and Drug Administration (FDA) work group to examine prescription drug importation policies.

  • HDA Statement on Senator McCaskill’s Opioid Report and the Role of Pharmaceutical Distributors in Addressing National Crisis
    July 12, 2018

    In response to a new report from Sen. Claire McCaskill (D-Mo.) regarding the role of distributors in addressing the country’s opioid abuse epidemic, Healthcare Distribution Alliance (HDA) President and CEO John M. Gray issued the following statement.

  • HDA Files Lawsuit to Block New York Opioid Law
    July 6, 2018

    Today, the Healthcare Distribution Alliance (HDA), the national trade association for pharmaceutical distributors, filed suit in the U.S. District Court for the Southern District of New York to block enforcement of New York’s Opioid Stewardship Act. The act imposes an unconstitutional $600 million punitive surcharge on pharmaceutical distributors and manufacturers. It bypasses judicial due process and impedes the industry’s comprehensive efforts to mitigate opioid abuse and misuse.

Website design and development by Americaneagle.com, inc
© 2018 Healthcare Distribution Alliance. All rights reserved.
HDA: M | C | D | NF | P | O365